Humberto Aguilar

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Jordan J. Feld, Kris V. Kowdley, Eoin Coakley et al. · New England Journal of Medicine · 2014 · 898 citations · Full text

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Xavier Forns, Samuel S. Lee, Joaquin Valdes et al. · The Lancet Infectious Diseases · 2017 · 338 citations

Hepatology, Hepatitis C, Viral Hepatitis +11

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Paul Y. Kwo, Fred Poordad, Armen Asatryan et al. · Journal of Hepatology · 2017 · 296 citations · Full text

Diagnostic Virology, Hepatology, Hepatitis C +9